Locoregional Therapy plus First-Line Systemic Therapy in Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma

Abstract Background and purpose Whether locoregional consolidation therapy (LCT) adds benefit to first-line systemic therapy in unresectable, locally advanced intrahepatic cholangiocarcinoma (ICC) is unknown. Methods In this single-centre retrospective cohort (2017–2025), 156 patients receiving gemcitabine-based chemotherapy plus a PD-1/PD-L1 inhibitor, with or without a tyrosine kinase inhibitor, were grouped by concomitant LCT (n = 61; radiotherapy 34, non-radiotherapy 27) or systemic therapy alone (n = 95). Stabilised inverse probability of treatment weighting (sIPTW) balanced 13 covariates; weighted Cox models and sensitivity analyses were used. Results At a median follow-up of 37.0 months, after stabilised inverse probability of treatment weighting, LCT was associated with longer progression-free survival (PFS; 17.35 vs 8.67 months; hazard ratio 0.43, 95% confidence interval 0.29–0.62; P < 0.001) and overall survival (OS; 28.91 vs 20.60 months; HR 0.59, 95% CI 0.39–0.91; P = 0.017). Across analytic approaches, hazard ratios were 0.41–0.55 for PFS and 0.49–0.71 for OS. E-values were 3.00 (PFS) and 2.23 (OS). Growth of existing intrahepatic lesions as the first progression was less frequent after radiotherapy-based consolidation (11.8% vs 41.1%; P = 0.002) but not after non-radiotherapy LCT (48.1% vs 41.1%; P = 0.52). Grade ≥ 3 lymphopenia (63.9% vs 33.7%), any-grade thrombocytopenia (82.0% vs 62.1%) and any-grade gastrointestinal ulceration (14.8% vs 2.1%) were more frequent with LCT, the ulcer excess being confined to radiotherapy-based consolidation (20.6% vs 2.1%; P = 0.001). Conclusion In unresectable ICC treated with first-line systemic therapy, consolidative LCT, and radiotherapy-based consolidation in particular, was associated with longer PFS and OS and fewer intrahepatic failures. Randomised confirmation is required.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11512602/v1
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Locoregional Therapy plus First-Line Systemic Therapy in Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma

Jiaoyang Yang, Huanliang Chen, Guo‐Ming Shi, Yanyan Lin et al.
Research Square
Cholangiocarcinoma and Gallbladder Cancer Studies
preprint

Locoregional Therapy plus First-Line Systemic Therapy in Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma

Jiaoyang Yang, Huanliang Chen, Guo‐Ming Shi, Yanyan Lin, Pan Zhou, Xiaojun Zhang, Kehao Liu, QIANQIAN ZHAO, Zhao-chong Zeng, Jian Zhou
preprint en

Abstract

Abstract Background and purpose Whether locoregional consolidation therapy (LCT) adds benefit to first-line systemic therapy in unresectable, locally advanced intrahepatic cholangiocarcinoma (ICC) is unknown. Methods In this single-centre retrospective cohort (2017–2025), 156 patients receiving gemcitabine-based chemotherapy plus a PD-1/PD-L1 inhibitor, with or without a tyrosine kinase inhibitor, were grouped by concomitant LCT (n = 61; radiotherapy 34, non-radiotherapy 27) or systemic therapy alone (n = 95). Stabilised inverse probability of treatment weighting (sIPTW) balanced 13 covariates; weighted Cox models and sensitivity analyses were used. Results At a median follow-up of 37.0 months, after stabilised inverse probability of treatment weighting, LCT was associated with longer progression-free survival (PFS; 17.35 vs 8.67 months; hazard ratio 0.43, 95% confidence interval 0.29–0.62; P < 0.001) and overall survival (OS; 28.91 vs 20.60 months; HR 0.59, 95% CI 0.39–0.91; P = 0.017). Across analytic approaches, hazard ratios were 0.41–0.55 for PFS and 0.49–0.71 for OS. E-values were 3.00 (PFS) and 2.23 (OS). Growth of existing intrahepatic lesions as the first progression was less frequent after radiotherapy-based consolidation (11.8% vs 41.1%; P = 0.002) but not after non-radiotherapy LCT (48.1% vs 41.1%; P = 0.52). Grade ≥ 3 lymphopenia (63.9% vs 33.7%), any-grade thrombocytopenia (82.0% vs 62.1%) and any-grade gastrointestinal ulceration (14.8% vs 2.1%) were more frequent with LCT, the ulcer excess being confined to radiotherapy-based consolidation (20.6% vs 2.1%; P = 0.001). Conclusion In unresectable ICC treated with first-line systemic therapy, consolidative LCT, and radiotherapy-based consolidation in particular, was associated with longer PFS and OS and fewer intrahepatic failures. Randomised confirmation is required.

Research Square
Zhongshan Hospital (CN)
National Natural Science Foundation of China, Fudan University, National Key Research and Development Program of China
Good health and well-being
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon